A Dark Vector Cognition product

Item 1. FINANCIAL STATEMENTS

52K characters. Original on sec.gov ·

Item 1. FINANCIAL STATEMENTS

The 38 tables in Item 1. FINANCIAL STATEMENTS as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Stryker Corporation and Subsidiaries

CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited)

Three Months
20232022
Net sales$4,778$4,275
Cost of sales1,7621,541
Gross profit$3,016$2,734
Research, development and engineering expenses339413
Selling, general and administrative expenses1,7811,710
Recall charges, net—14
Amortization of intangible assets161150
Total operating expenses$2,281$2,287
Operating income$735$447
Other income (expense), net(56)(61)
Earnings before income taxes$679$386
Income taxes8763
Net earnings$592$323
Net earnings per share of common stock:
Basic$1.56$0.86
Diluted$1.54$0.84
Weighted-average shares outstanding (in millions):
Basic379.0377.7
Effect of dilutive employee stock compensation4.25.0
Diluted383.2382.7
Cash dividends declared per share of common stock$0.750$0.695

Anti-dilutive shares excluded from the calculation of dilutive employee stock options were de minimis in all periods.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)

Three Months
20232022
Net earnings$592$323
Other comprehensive income (loss), net of tax:
Marketable securities—(1)
Pension plans(2)(1)
Unrealized gains (losses) on designated hedges(9)1
Financial statement translation(73)53
Total other comprehensive income (loss), net of tax$(84)$52
Comprehensive income$508$375

See accompanying notes to Consolidated Financial Statements.

Dollar amounts are in millions except per share amounts or as otherwise specified.1
STRYKER CORPORATION2023 First Quarter Form 10-Q

CONSOLIDATED BALANCE SHEETS

March 31December 31
20232022
(Unaudited)
Assets
Current assets
Cash and cash equivalents$1,671$1,844
Marketable securities8684
Accounts receivable, less allowance of $180 ($154 in 2022)3,2153,565
Inventories:
Materials and supplies1,1441,006
Work in process366348
Finished goods2,8232,641
Total inventories$4,333$3,995
Prepaid expenses and other current assets850787
Total current assets$10,155$10,275
Property, plant and equipment:
Land, buildings and improvements1,7701,739
Machinery and equipment4,2004,066
Total property, plant and equipment$5,970$5,805
Less allowance for depreciation2,9332,835
Property, plant and equipment, net$3,037$2,970
Goodwill14,84914,880
Other intangibles, net4,7794,885
Noncurrent deferred income tax assets1,4431,410
Other noncurrent assets2,5672,464
Total assets$36,830$36,884
Liabilities and shareholders' equity
Current liabilities
Accounts payable$1,366$1,413
Accrued compensation7131,149
Income taxes371292
Dividends payable285284
Accrued product liabilities227230
Accrued expenses and other liabilities1,7001,744
Current maturities of debt1,2041,191
Total current liabilities$5,866$6,303
Long-term debt, excluding current maturities11,85711,857
Income taxes625641
Other noncurrent liabilities1,5871,467
Total liabilities$19,935$20,268
Shareholders' equity
Common stock, $0.10 par value3838
Additional paid-in capital2,0902,034
Retained earnings15,07214,765
Accumulated other comprehensive loss(305)(221)
Total shareholders' equity$16,895$16,616
Total liabilities and shareholders' equity$36,830$36,884

See accompanying notes to Consolidated Financial Statements.

Dollar amounts are in millions except per share amounts or as otherwise specified.2
STRYKER CORPORATION2023 First Quarter Form 10-Q

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited)

Three Months
20232022
Common stock shares outstanding (in millions)
Beginning378.7377.5
Issuance of common stock under stock compensation and benefit plans0.90.7
Ending379.6378.2
Common stock
Beginning$38$38
Issuance of common stock under stock compensation and benefit plans——
Ending$38$38
Additional paid-in capital
Beginning$2,034$1,890
Issuance of common stock under stock compensation and benefit plans(18)(14)
Share-based compensation7471
Ending$2,090$1,947
Retained earnings
Beginning$14,765$13,480
Net earnings592323
Cash dividends declared(285)(263)
Ending$15,072$13,540
Accumulated other comprehensive income (loss)
Beginning$(221)$(531)
Other comprehensive income (loss)(84)52
Ending$(305)$(479)
Total shareholders' equity$16,895$15,046

See accompanying notes to Consolidated Financial Statements.

Dollar amounts are in millions except per share amounts or as otherwise specified.3
STRYKER CORPORATION2023 First Quarter Form 10-Q

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

Three Months
20232022
Operating activities
Net earnings$592$323
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation9692
Amortization of intangible assets161150
Asset impairments2—
Share-based compensation7471
Recall charges, net—14
Sale of inventory stepped-up to fair value at acquisition—5
Changes in operating assets and liabilities:
Accounts receivable36553
Inventories(314)(229)
Accounts payable(56)(52)
Accrued expenses and other liabilities(405)(348)
Recall-related payments(14)(9)
Income taxes23(3)
Other, net(79)136
Net cash provided by operating activities$445$203
Investing activities
Acquisitions, net of cash acquired—(2,563)
Purchases of marketable securities(28)(9)
Proceeds from sales of marketable securities2511
Purchases of property, plant and equipment(130)(119)
Other investing, net1(2)
Net cash used in investing activities$(132)$(2,682)
Financing activities
Proceeds (payments) on short-term borrowings, net(2)(170)
Proceeds from issuance of long-term debt—1,500
Payments on long-term debt(100)—
Payments of dividends(284)(262)
Cash paid for taxes from withheld shares(94)(72)
Other financing, net(1)(3)
Net cash provided by (used in) financing activities$(481)$993
Effect of exchange rate changes on cash and cash equivalents(5)—
Change in cash and cash equivalents$(173)$(1,486)
Cash and cash equivalents at beginning of period1,8442,944
Cash and cash equivalents at end of period$1,671$1,458

See accompanying notes to Consolidated Financial Statements.

Dollar amounts are in millions except per share amounts or as otherwise specified.4
STRYKER CORPORATION2023 First Quarter Form 10-Q

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

NOTE 1 - BASIS OF PRESENTATION

General Information

Management believes the accompanying unaudited Consolidated Financial Statements contain all adjustments, including normal recurring items, considered necessary to fairly present the financial position of Stryker Corporation and its consolidated subsidiaries ("Stryker," the "Company," "we," "us" or "our") on March 31, 2023 and the results of operations for the three months 2023. The results of operations included in these Consolidated Financial Statements may not necessarily be indicative of our annual results. These statements should be read in conjunction with our Annual Report on Form 10-K for 2022. Certain immaterial reclassifications have been made to prior year's segment operating income to conform with current year presentation in our Consolidated Financial Statements.

New Accounting Pronouncements Not Yet Adopted

We evaluate all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in our disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on our Consolidated Financial Statements.

NOTE 2 - REVENUE RECOGNITION

Our policies for recognizing sales have not changed from those described in our Annual Report on Form 10-K for 2022.

We disaggregate our net sales by business and geographic location for each of our segments as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors.

Beginning in the first quarter of 2023, we consolidated Other MedSurg and Neurotechnology into Endoscopy as Other MedSurg and Neurotechnology (primarily Sustainability Solutions) has been fully integrated into our Endoscopy business. Endoscopy includes sales related to Other of $81 and $69 for the three months 2023 and 2022. We have reflected these changes in all historical periods presented.

Net Sales by Business
Three Months
20232022
MedSurg and Neurotechnology:
Instruments$575$528
Endoscopy698607
Medical778664
Neurovascular284301
Neuro Cranial355323
$2,690$2,423
Orthopaedics and Spine:
Knees$566$464
Hips375327
Trauma and Extremities769685
Spine284279
Other9497
$2,088$1,852
Total$4,778$4,275
Net Sales by Geography
Three Months 2023Three Months 2022
United StatesInternationalUnited StatesInternational
MedSurg and Neurotechnology:
Instruments$450$125$414$114
Endoscopy564134486121
Medical612166525139
Neurovascular118166110191
Neuro Cranial2896626459
$2,033$657$1,799$624
Orthopaedics and Spine:
Knees$416$150$345$119
Hips236139202125
Trauma and Extremities554215487198
Spine2127220079
Other61337225
$1,479$609$1,306$546
Total$3,512$1,266$3,105$1,170

Contract Assets and Liabilities

On March 31, 2023 and December 31, 2022 contract assets recorded in our Consolidated Balance Sheets were not significant.

Our contract liabilities arise as a result of consideration received from customers at inception of contracts for certain businesses or where the timing of billing for services precedes satisfaction of our performance obligations. This occurs primarily when payment is received upfront for certain multi-period extended service contracts. Our contract liabilities of $757 and $741 on March 31, 2023 and December 31, 2022 are classified within accrued expenses and other liabilities and other noncurrent liabilities within our consolidated balance sheets based on the timing of when we expect to complete our performance obligations.

Changes in contract liabilities during the year were as follows:

March 2023
Beginning contract liabilities$741
Revenue recognized from beginning of year contract liabilities(129)
Net advance consideration received during the period145
Ending contract liabilities$757

NOTE 3 - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (AOCI)

Three Months 2023Marketable SecuritiesPension PlansHedgesFinancial Statement TranslationTotal
Beginning$(1)$31$52$(303)$(221)
OCI—23(99)(94)
Income taxes—(3)(1)3228
Reclassifications to:
Cost of sales——(13)—(13)
Other (income) expense, net—(1)(1)(8)(10)
Income taxes——325
Net OCI—(2)(9)(73)(84)
Ending$(1)$29$43$(376)$(305)
Dollar amounts are in millions except per share amounts or as otherwise specified.5
STRYKER CORPORATION2023 First Quarter Form 10-Q
Three Months 2022Marketable SecuritiesPension PlansHedgesFinancial Statement TranslationTotal
Beginning$—$(155)$40$(416)$(531)
OCI(1)(4)48685
Income taxes—2(2)(25)(25)
Reclassifications to:
Other (income) expense, net—2(1)(11)(10)
Income taxes—(1)—32
Net OCI(1)(1)15352
Ending$(1)$(156)$41$(363)$(479)

NOTE 4 - DERIVATIVE INSTRUMENTS

We use operational and economic hedges, foreign currency exchange forward contracts, net investment hedges (both derivative and non-derivative financial instruments) and interest rate derivative instruments to manage the impact of currency exchange and interest rate fluctuations on earnings, cash flow and equity. We do not enter into derivative instruments for speculative purposes. We are exposed to potential credit loss in the event of nonperformance by counterparties on our outstanding derivative instruments but do not anticipate nonperformance by any of our counterparties. Should a counterparty default, our maximum loss exposure is the asset balance of the instrument. We have not changed our hedging strategies, accounting practices or objectives from those disclosed in our Annual Report on Form 10-K for 2022.

Foreign Currency Hedges

March 2023Cash FlowNet InvestmentNon-DesignatedTotal
Gross notional amount$1,109$1,636$3,268$6,013
Maximum term in years3.6
Fair value:
Other current assets$14$—$9$23
Other noncurrent assets178—79
Other current liabilities(5)—(46)(51)
Other noncurrent liabilities—(25)—(25)
Total fair value$10$53$(37)$26
December 2022Cash FlowNet InvestmentNon-DesignatedTotal
Gross notional amount$1,053$1,598$3,417$6,068
Maximum term in years3.9
Fair value:
Other current assets$20$—$9$29
Other noncurrent assets189—90
Other current liabilities(6)—(79)(85)
Other noncurrent liabilities(1)(16)—(17)
Total fair value$14$73$(70)$17

We had €1.5 billion at March 31, 2023 and December 31, 2022 in certain forward currency contracts designated as net investment hedges to hedge a portion of our investments in certain of our entities with functional currencies denominated in Euros. In addition to these derivative financial instruments designated as net investment hedges, we had €4.4 billion at March 31, 2023 and December 31, 2022 of senior unsecured notes designated as net investment hedges to selectively hedge portions of our investment in certain international subsidiaries. The currency effects of our Euro-denominated senior unsecured notes are reflected in AOCI within shareholders' equity where they offset gains and losses recorded on our net investment in international subsidiaries.

The total after-tax gain (loss) recognized in OCI related to designated net investment hedges was ($106) in the three months 2023.

Net Currency Exchange Rate Gains (Losses)

DerivativeThree Months
instrument:Recorded in:20232022
Cash FlowCost of sales$13$—
Net InvestmentOther income (expense), net811
Non-DesignatedOther income (expense), net(4)1
Total$17$12

Pretax gains (losses) on derivatives designated as cash flow hedges of $20 and net investment hedges of $34 recorded in AOCI are expected to be reclassified to cost of sales and other income (expense), net in earnings within 12 months as of March 31, 2023. This cash flow hedge reclassification is primarily due to the sale of inventory that includes previously hedged purchases. A component of the AOCI amounts related to net investment hedges is reclassified over the life of the hedge instruments as we elected to exclude the initial value of the component related to the spot-forward difference from the effectiveness assessment.

Interest Rate Hedges

Pretax gains of $5 recorded in AOCI related to other interest rate hedges closed in conjunction with debt issuances are expected to be reclassified to other income (expense), net in earnings within 12 months of March 31, 2023. The cash flow effect of interest rate hedges is recorded in cash flow from operations.

NOTE 5 - FAIR VALUE MEASUREMENTS

Our policies for managing risk related to foreign currency, interest rates, credit and markets and our process for determining fair value have not changed from those described in our Annual Report on Form 10-K for 2022.

In the third quarter 2022 we determined that certain commercial and regulatory milestones related to technology acquired in the purchase of Mobius Imaging and Cardan Robotics were no longer probable of being achieved and recorded a $110 reduction in the fair value of contingent consideration reflected in selling, general and administrative expenses.

There were no significant transfers into or out of any level of the fair value hierarchy in 2023.

Assets Measured at Fair ValueMarchDecember
20232022
Cash and cash equivalents$1,671$1,844
Trading marketable securities179166
Level 1 - Assets$1,850$2,010
Available-for-sale marketable securities:
Corporate and asset-backed debt securities$41$42
Foreign government debt securities11
United States agency debt securities63
United States treasury debt securities3736
Certificates of deposit12
Total available-for-sale marketable securities$86$84
Foreign currency exchange forward contracts102119
Level 2 - Assets$188$203
Total assets measured at fair value$2,038$2,213
Dollar amounts are in millions except per share amounts or as otherwise specified.6
STRYKER CORPORATION2023 First Quarter Form 10-Q
Liabilities Measured at Fair ValueMarchDecember
20232022
Deferred compensation arrangements$179$166
Level 1 - Liabilities$179$166
Foreign currency exchange forward contracts$76$102
Level 2 - Liabilities$76$102
Contingent consideration:
Beginning$121$306
Additions—1
Change in estimate and foreign exchange—(137)
Settlements(1)(49)
Ending$120$121
Level 3 - Liabilities$120$121
Total liabilities measured at fair value$375$389
Fair Value of Available for Sale Securities by Maturity
March 2023December 2022
Due in one year or less$51$53
Due after one year through three years$35$31

On March 31, 2023 and December 31, 2022 the aggregate difference between the cost and fair value of available-for-sale marketable securities was nominal. Interest on cash and cash equivalents, short-term investments and marketable securities income was $14 and $15 in the three months 2023 and 2022, which was recorded in other income (expense), net.

Our investments in available-for-sale marketable securities had a minimum credit quality rating of A2 (Moody's), A (Standard & Poor's) and A (Fitch). We do not plan to sell the investments, and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity.

NOTE 6 - CONTINGENCIES AND COMMITMENTS

We are involved in various ongoing proceedings, legal actions and claims arising in the normal course of business, including proceedings related to product, labor, intellectual property and other matters, the most significant of which are more fully described below. The outcomes of these matters will generally not be known for prolonged periods of time. In certain of the legal proceedings the claimants seek damages as well as other compensatory and equitable relief that could result in the payment of significant claims and settlements and/or the imposition of injunctions or other equitable relief. For legal matters for which management had sufficient information to reasonably estimate our future obligations, a liability representing management's best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within the range is not known, is recorded. The estimates are based on consultation with legal counsel, previous settlement experience and settlement strategies. If actual outcomes are less favorable than those estimated by management, additional expense may be incurred, which could unfavorably affect future operating results. We are self-insured for certain claims and expenses. The ultimate cost to us with respect to product liability claims could be materially different than the amount of the current estimates and accruals and could have a material adverse effect on our financial position, results of operations and cash flows.

In April 2022 the United States District Court for the District of Delaware issued a judgment following a jury verdict in favor of PureWick Corporation (PureWick) for its 2019 complaint seeking patent infringement damages related to our PrimaFit and PrimoFit products. Following a jury trial, the court awarded damages related to this complaint and we recorded charges of $28 in March 2022. Stryker plans to appeal the results of the trial. In June 2022 PureWick filed a motion to enhance the damages awarded, which the court denied in March 2023. In 2022

PureWick also filed a separate complaint seeking additional patent infringement damages related to our PrimaFit products.

We are currently investigating whether certain business activities in a foreign country violated provisions of the Foreign Corrupt Practices Act (FCPA) and have engaged outside counsel to conduct this investigation. We have been contacted by the United States Securities and Exchange Commission and United States Department of Justice and are cooperating with both agencies. At this time we are unable to predict the outcome of the investigation or the potential impact, if any, on our financial statements.

Recall Matters

We have conducted voluntary recalls of certain products, including our Rejuvenate and ABG II Modular-Neck hip stems and certain lot-specific sizes and offsets of LFIT Anatomic CoCr V40 Femoral Heads. Additionally, we are responsible for certain product liability claims, primarily related to certain hip products sold by Wright Medical Group N.V. (Wright) prior to its 2014 divestiture of the OrthoRecon business.

We have incurred, and expect to incur in the future, costs associated with the defense and settlement of claims and lawsuits related to our recalls. Based on the information that has been received, we have recorded reserves of $202, representing our best estimate of probable loss related to recall matters globally. The final outcomes of these matters are dependent on many factors that are difficult to predict. Accordingly the ultimate cost related to these matters may be materially different than the amount of our current estimate and accruals and could have a material adverse effect on our results of operations and cash flows.

LeasesMarchDecember
20232022
Right-of-use assets$489$473
Lease liabilities, current$132$121
Lease liabilities, non-current$367$357
Other information:
Weighted-average remaining lease term (years)5.35.5
Weighted-average discount rate3.40%3.22%
Three Months
20232022
Operating lease cost$38$31

NOTE 7 - ACQUISITIONS

We acquire stock in companies and various assets that continue to support our capital deployment and product development strategies. There were no acquisitions in the three months 2023. The aggregate purchase price of our acquisitions, net of cash acquired was $2,563 in the three months 2022.

In February 2022 we completed the acquisition of Vocera Communications, Inc. (Vocera) for $79.25 per share, or an aggregate purchase price of $2.6 billion, net of cash acquired ($3.0 billion including convertible notes). Vocera is a leader in the digital care coordination and communication category. Vocera is part of our Medical business within MedSurg and Neurotechnology. Goodwill attributable to the acquisition reflects the strategic benefits of expanding our presence in adjacent markets, diversifying our product portfolio, advancing innovations, and accelerating our digital aspirations. This goodwill is not deductible for tax purposes.

Dollar amounts are in millions except per share amounts or as otherwise specified.7
STRYKER CORPORATION2023 First Quarter Form 10-Q

In the three months 2022 note holders elected to redeem the 1.50% and 0.50% convertible notes assumed in the Vocera acquisition for $101 and $324. These repayments are classified as financing activities in the Consolidated Statements of Cash Flows.

Share-based awards for Vocera employees vested upon our acquisition and a charge of $132 was recorded in selling, general and administrative expenses in 2022.

Purchase price allocations for our significant acquisitions are:

Purchase Price Allocation of Acquired Net Assets
2022Vocera
Tangible assets acquired:
Accounts receivable$33
Inventory13
Deferred income tax assets91
Other assets92
Debt(425)
Deferred income tax liabilities(193)
Other liabilities(117)
Intangible assets:
Customer and distributor relationships603
Developed technology175
Trade name18
Goodwill2,273
Purchase price, net of cash acquired of $281$2,563
Weighted average amortization period at acquisition (years):
Developed technologies6
Customer relationships15
Trademarks9

The purchase price allocation for Vocera was finalized in the three months 2023 without material adjustments.

On May 2, 2023 we acquired Cerus Endovascular Limited (Cerus) for $300 in cash and up to $225 in future milestone payments. Cerus designs, develops and manufactures neurovascular products used for the treatment of hemorrhagic stroke. We plan to integrate Cerus into our Neurovascular business within MedSurg and Neurotechnology.

Consolidated Estimated Amortization Expense
Remainder of 20232024202520262027
$463$590$571$514$493

NOTE 8 - DEBT AND CREDIT FACILITIES

We have lines of credit issued by various financial institutions that are available to fund our day-to-day operating needs. Our credit facilities require us to comply with financial and other covenants. We were in compliance with all covenants on March 31, 2023.

In February 2022 we entered into a $1.5 billion term loan agreement that matures on February 22, 2025 and bears interest at a base rate based on the Term Secured Overnight Financing Rate (SOFR) plus 0.725%. Through March 31, 2023 we have repaid $750 on the term loan.

In the first quarter of 2022 our Board of Directors approved an increase to the maximum amount of commercial paper that can be outstanding from $1,500 to $2,250.

On March 31, 2023 there were no borrowings outstanding under our revolving credit facility or our commercial paper program which allows for maturities up to 397 days from the date of issuance.

Summary of Total DebtMarch 2023December 2022
RateDue
Senior unsecured notes:
1.125%November 30, 2023$599$585
0.600%December 1, 2023599599
3.375%May 15, 2024597596
0.250%December 3, 2024925903
1.150%June 15, 2025647647
3.375%November 1, 2025748748
3.500%March 15, 2026996995
2.125%November 30, 2027814795
3.650%March 7, 2028597597
0.750%March 1, 2029868848
1.950%June 15, 2030991991
2.625%November 30, 2030701684
1.000%December 3, 2031809790
4.100%April 1, 2043392392
4.375%May 15, 2044395396
4.625%March 15, 2046983983
2.900%June 15, 2050642642
Term loan750850
Other87
Total debt$13,061$13,048
Less current maturities1,2041,191
Total long-term debt$11,857$11,857
March 2023December 2022
Unamortized debt issuance costs$51$52
Borrowing capacity on existing facilities$2,160$2,162
Fair value of senior unsecured notes$11,274$10,910

The fair value of the senior unsecured notes was estimated using quoted interest rates, maturities and amounts of borrowings based on quoted active market prices and yields that took into account the underlying terms of the debt instruments. Substantially all of our debt is classified within Level 2 of the fair value hierarchy.

NOTE 9 - INCOME TAXES

Our effective tax rates were 12.8% and 16.3% in the three months 2023 and 2022. The effective tax rates for the three months 2023 and 2022 reflect the continued lower effective income tax rates as a result of our European operations and certain discrete tax items.

NOTE 10 - SEGMENT INFORMATION

Three Months
20232022
MedSurg and Neurotechnology$2,690$2,423
Orthopaedics and Spine2,0881,852
Net sales$4,778$4,275
MedSurg and Neurotechnology$627$630
Orthopaedics and Spine601503
Segment operating income$1,228$1,133
Items not allocated to segments:
Corporate and other$(222)$(199)
Acquisition and integration-related costs(6)(149)
Amortization of intangible assets(161)(150)
Structural optimization and other special charges(42)(109)
Medical device regulations(28)(28)
Recall-related matters—(14)
Regulatory and legal matters(34)(37)
Consolidated operating income$735$447

There were no significant changes to total assets by segment from information provided in our Annual Report on Form 10-K for 2022.

Dollar amounts are in millions except per share amounts or as otherwise specified.8
STRYKER CORPORATION2023 First Quarter Form 10-Q

Previous: Cover and table of contents · Next: Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS